Section Arrow
CRSP.NASDAQ
- CRISPR Therapeutics AG
Quotes are at least 15-min delayed:2026/01/09 09:08 EST
Pre Market
Last
 57.2384
+0.8384 (+1.49%)
Bid
57.18
Ask
57.24
High 57.48 
Low 56 
Volume 12.60K 
Regular Hours (Closed)
Last
 --
-- (--)
Day High 
-- 
Prev. Close
56.4 
1-M High
60.73 
Volume 
-- 
Bid
57.18
Ask
57.24
Day Low
-- 
Open
-- 
1-M Low
52.1 
Market Cap 
5.37B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 55.29 
20-SMA 55.86 
50-SMA 55.63 
52-W High 78.48 
52-W Low 30.04 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-5.54/-2.52
Enterprise Value
5.58B
Balance Sheet
Book Value Per Share
20.10
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
35.00M
Operating Revenue Per Share
1.78
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ZYMEZymeworks-------- 
Pre Market 23.3 +0.2 +0.87%
ZVRAZevra Therapeutics-------- 
Pre Market 8.65 +0.02 +0.23%
ZURAZura Bio Limited-------- 
Pre Market 5.26 0 0.00%
ZNTLZentalis Pharmaceuticals-------- 
Pre Market 3.18 +0.34 +11.97%
ZLABZai Lab Limited-------- 
Pre Market 18.6 +0.1 +0.54%
Industry overview quotes are at least 15 minutes delayed
Business Description
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), whichis a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.